IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment
Hu Da-yi2; Huang Jun3; Cai Nai-sheng4; Zhu Wen-ling5; Li Yi-shi6; Massaad, Rachid7; Hanson, Mary E.8; Dickstein, Kenneth1
关键词angiotensin converting enzyme inhibitor heart failure losartan
刊名CHINESE MEDICAL JOURNAL
2012-11-05
DOI10.3760/cma.j.issn.0366-6999.2012.21.023
125期:21页:3868-3874
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Merck Sharp Dohme Corp. ; Merck Sharp Dohme Corp.
研究领域[WOS]General & Internal Medicine
关键词[WOS]VENTRICULAR SYSTOLIC FUNCTION ; TRIAL ; VALSARTAN ; DYSFUNCTION ; CANDESARTAN ; MANAGEMENT ; CAPTOPRIL ; HYPERTENSION ; TELMISARTAN ; GUIDELINES
英文摘要

Background There have been no mortality/morbidity endpoint studies with losartan in Chinese heart failure patients. The objective was to evaluate the effects of high-dose vs. low-dose losartan on clinical outcomes in Chinese subjects with heart failure.

Methods This study was a post hoc analysis of the Heart failure Endpoint evaluation of Angiotensin II Antagonist losartan (HEAAL) trial (n=545). Chinese adults with symptomatic heart failure (New York Heart Association (NYHA) II-IV) intolerant of treatment with angiotensin converting enzyme (ACE) inhibitors were randomized to losartan 150 mg or 50 mg daily. The primary endpoint was the composite event rate of all-cause death or hospitalization for heart failure. Safety and tolerability were assessed.

Results Median follow-up was 4.8 years. Baseline characteristics were generally similar to the overall HEAAL cohort. Overall, 120 (44.1%) subjects in the losartan 150 mg group and 137 (50.2%) subjects in the losartan 50 mg group died (any cause) or were hospitalized for heart failure (hazard ratio (OR) 0.807, 95% CI 0.631-1.031). There were no notable differences between treatment groups in the proportion of subjects with adverse experiences.

Conclusion The results of this post hoc analysis in Chinese subjects, although not powered to show significance, were generally consistent with the main study results, which demonstrated a significantly reduced risk of all cause death or hospitalization for heart failure with daily losartan 150 mg vs. losartan 50 mg in subjects with symptomatic heart failure and intolerance to ACE inhibitors, supporting the use of the higher dose for optimum clinical benefit. Chin Med J 2012;125(21):3868-3874

语种英语
资助者Merck Sharp Dohme Corp. ; Merck Sharp Dohme Corp.
WOS记录号WOS:000311265200023
Citation statistics
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61371
Collection北京大学第二临床医学院_心血管内科
作者单位1.Univ Bergen, Div Cardiol, Stavanger Univ Hosp, Dept Cardiol, N-4011 Stavanger, Norway
2.Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100044, Peoples R China
3.Jiangsu Prov Hosp, Dept Cardiol, Nanjing 210029, Jiangsu, Peoples R China
4.Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China
5.Beijing Union Med Coll Hosp, Dept Cardiol, Beijing 100730, Peoples R China
6.Fu Wai Hosp, Clin Pharmacol Ctr, Beijing 100037, Peoples R China
7.MSD Europe Inc, Dept Biostat, Brussels, Belgium
8.Merck Sharp & Dohme Corp, Global Sci & Med Publicat, Whitehouse Stn, NJ USA
Recommended Citation
GB/T 7714
Hu Da-yi,Huang Jun,Cai Nai-sheng,et al. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment[J]. CHINESE MEDICAL JOURNAL,2012,125(21):3868-3874.
APA Hu Da-yi.,Huang Jun.,Cai Nai-sheng.,Zhu Wen-ling.,Li Yi-shi.,...&Dickstein, Kenneth.(2012).A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.CHINESE MEDICAL JOURNAL,125(21),3868-3874.
MLA Hu Da-yi,et al."A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment".CHINESE MEDICAL JOURNAL 125.21(2012):3868-3874.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Hu Da-yi]'s Articles
[Huang Jun]'s Articles
[Cai Nai-sheng]'s Articles
百度学术
百度学术Similar articles in
[Hu Da-yi]'s Articles
[Huang Jun]'s Articles
[Cai Nai-sheng]'s Articles
必应学术
必应学术Similar articles in
[Hu Da-yi]'s Articles
[Huang Jun]'s Articles
[Cai Nai-sheng]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.